logo

Flexion Therapeutics, Inc. (FLXN)



Trade FLXN now with
  Date
  Headline
10/14/2019 7:07:11 AM Flexion Therapeutics Report Extended FDA Review Of Supplemental NDA For ZILRETTA
1/22/2019 4:34:35 PM Flexion Therapeutics Names Christina Willwerth Chief Strategy Officer
12/26/2018 12:40:01 AM 8 Biotech Stocks To Watch This Week
11/5/2018 6:35:29 AM Flexion Therapeutics Says CMS Issues Product-specific J Code For ZILRETTA
10/22/2018 7:40:50 AM Flexion Therapeutics To Present Results From Phase 2 Trial Of ZILRETTA
5/7/2018 7:33:57 AM Flexion Therapeutics Appoints David Arkowitz As CFO
5/4/2018 7:36:04 AM Flexion Therapeutics Announces ZILRETTA Recommended For Unique J Code By CMS
4/26/2018 7:39:08 AM Flexion Therapeutics Presents Updated Results From Clinical Trial On Repeat Administration Of ZILRETTA
4/6/2018 4:40:13 PM Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
1/8/2018 7:40:43 AM Flexion Therapeutics Announces Initial Data From Clinical Trial Evaluating Repeat Administration Of ZILRETTA
  
 
>